An observational study in Thalassemia, Beta, sponsored by Bioray Laboratories. Recruiting at 7 sites in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Bioray Laboratories · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.
Among the 44 studies in beta-Thalassemia with a site in China, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2024, is one of 10 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 33rd registered.
295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.
Browse beta-Thalassemia studies →20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18–65
Guangzhou Women and Children's Medical Center · Sites in China
Ages 7–10
Children's Hospital of Fudan University · Sites in China
Ages 3–17
Kanglin Biotechnology (Hangzhou) Co., Ltd. · Sites in China
Ages 3–35
Shanghai BDgene Co., Ltd. · Sites in China
Ages 6–35
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 3 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1 · Phase 4 4
First in 2012; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 100 across 75 observational studies indexed under beta-Thalassemia.
Median enrollment 10 across the 34 interventional studies, 96 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bioray Laboratories, one of the names counted as BRL Medicine Inc.. Under that name alone:
Bioray Laboratories is the lead sponsor of 24 studies on the registry; 14 are open to participants now.
BRL Medicine Inc. has 6 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
4 of the studies in beta-Thalassemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479616Children's Hospital of Fudan UniversityA Long-term Follow-up Study in Participants Who Received CS-101 | 2026-12 |
| NCT06308159Lantu BiopharmaAn Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia | 2027-08-01 |
| NCT05860595Institute of Hematology & Blood Diseases Hospital, ChinaEvaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. | 2027-08-20 |
| NCT06280378Kanglin Biotechnology (Hangzhou) Co., Ltd.β-Thalassemia Treatment With KL003 Cell Injection | 2027-11-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in beta-Thalassemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Subjects with transfusion-dependent β-thalassemia who have been treated with BRL-101.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- There are no exclusion criteria for this study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who have received BRL-101
Other: Assessments
Safety and efficacy assessments
Incidence of hematologic malignancies
Such as new lymphoma, leukemia, MDS, etc.
Time frame: Up to 15 years post-drug product infusion
Frequency, grade, and relationship of SAEs
Frequency, grade, and relationship to BRL-101 of SAEs following BRL-101 reinfusion.
Time frame: Within 2 years to 5years after BRL-101 Infusion
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Aug 2038, 164 months after the start.
Of 29 observational studies under beta-Thalassemia, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 156. This study's planned 164 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.